Host, parasite and drug determinants of clinical outcomes following treatment of visceral leishmaniasis: a protocol for individual participant data meta-analysis

INTRODUCTION: Visceral leishmaniasis (VL) is a parasitic disease with an estimated 30 000 new cases occurring annually. There is an observed variation in the efficacy of the current first-line therapies across different regions. Such heterogeneity could be a function of host, parasite and drug facto...

Descripción completa

Detalles Bibliográficos
Autores principales: Kumar, Rishikesh, Dahal, Prabin, Singh-Phulgenda, Sauman, Siddiqui, Niyamat Ali, Munir, Abdalla, Naylor, Caitlin, Wilson, James, Buck, Gemma, Rahi, Manju, Malaviya, Paritosh, Alves, Fabiana, Sundar, Shyam, Ritmeijer, Koert, Stepniewska, Kasia, Guérin, Philippe J, Pandey, Krishna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Global Health
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10618999/
https://www.ncbi.nlm.nih.gov/pubmed/37898487
http://dx.doi.org/10.1136/bmjopen-2023-074679

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10618999/
https://www.ncbi.nlm.nih.gov/pubmed/37898487
http://dx.doi.org/10.1136/bmjopen-2023-074679

Ejemplares similares